8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 10, 2022)

Filed February 10, 2022For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) announced its financial results for the fourth quarter and full year ended December 31, 2021, via a press release furnished as part of this Form 8-K filing. While the filing itself doesn't contain the detailed financial figures within the 8-K document, it directs investors to the accompanying press release (Exhibit 99.1) for comprehensive information on operational performance and financial condition. This includes key metrics, revenue generation, expenses, and profitability for the periods presented. Investors should refer to the press release dated February 10, 2022, for the specific financial details and operational highlights. This 8-K serves as a notification of the release of this information, which is crucial for understanding the company's recent performance and future outlook. The filing also notes that the information furnished under Item 2.02 is not considered "filed" for certain regulatory purposes, but it is the primary source for the reported results.

Key Highlights

  • 1Alnylam Pharmaceuticals announced its Q4 and full-year 2021 financial results on February 10, 2022.
  • 2The detailed financial results and operational performance are available in the press release furnished as Exhibit 99.1.
  • 3Investors need to consult the press release for specific financial data, including revenue, expenses, and profitability.
  • 4The filing serves as a notification mechanism for the earnings release.
  • 5The information furnished under Item 2.02 is not deemed 'filed' under Section 18 of the Exchange Act.
  • 6The company provided information regarding its financial condition and results of operations for the periods ending December 31, 2021.

Frequently Asked Questions

The specific financial results for the quarter and year ended December 31, 2021, are detailed in the press release issued by Alnylam Pharmaceuticals on February 10, 2022, which is furnished as Exhibit 99.1 to this Form 8-K filing.

This 8-K filing itself does not contain the detailed financial metrics. Investors should refer to the accompanying press release (Exhibit 99.1) for information on revenue, earnings, expenses, and other relevant financial data for the periods ending December 31, 2021.

The information furnished under Item 2.02 of this Form 8-K, including the press release, is not deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, nor is it subject to the liabilities of that section, unless specifically incorporated by reference into a filing.

This 8-K filing's primary significance for investors is to formally announce and provide access to Alnylam Pharmaceuticals' Q4 and full-year 2021 financial results and operational performance, as detailed in the furnished press release. It serves as the official notification of this important company update.